MASSDEVICE ON CALL — The 2.3% sales tax enacted by the Affordable Care Act isn’t a fan favorite among medical device makers, but there may be room for investors to find new opportunities.

The tax may make young companies more attractive targets and patent portfolios more valuable, for example.

Emerging device maker among the hardest hit by the medtech tax, since the levy applies to sales of even pre-profit device companies, but development-stage groups may have the power to "plan ahead for the tax and adjust their sales strategy in advance instead of cost cutting," according to Wall Street Cheat Sheet.

In addition, the tax does not apply to companies that license their patents to other firms, applying instead to the licensors, making portfolio companies alluring buys.

 House bill would jail Obamacare identity fraudsters
A Republican bill proposed this month would mandate a 5-year prison sentence for those convicted of stealing Obamacare data to conduct identity fraud.
Read more

 DePuy hip lawsuits number over 5,000
The month of November saw 100 new patient lawsuits filed over Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopaedics’ recalled metal-on-metal hip implants, bringing the total to more than 5,000.
Read more

 Edwards Lifesciences doles out $5.6M to non-profits
Massachusetts medtech giant Edwards Lifesciences (NYSE:EW) plans to award a total of $5.6 million to more than 450 non-profit groups supporting health- and community-focused initiatives.
Read more

 Scam Obamacare site hits D.C.
Scammers have set up a fraudulent Obamacare health exchange website designed to lure D.C. patients to divulge their personal information, a scam that local authorities called "not a major problem."
Read more